ISSN 1662-4009 (online)

ey0019.14-15 | Genetics | ESPEYB19

14.15. Whole-genome risk prediction of common diseases in human preimplantation embryos

Kumar Akash , Im Kate , Banjevic Milena , Ng Pauline C , Tunstall Tate , Garcia Geronimo , Galhardo Luisa , Sun Jiayi , Schaedel Oren N , Levy Brynn , Hongo Donna , Kijacic Dusan , Kiehl Michelle , Tran Nam D , Klatsky Peter C , Rabinowitz Matthew

Nat Med. 2022 Mar;28(3):513–516. doi: 10.1038/s41591-022-01735-0. Epub 2022 Mar 21.Brief Summary: Currently, preimplantation genetic testing (PGT) is used to avoid specific rare Mendelian disorders before in-vitro fertilization (IVF). However, evidence is limited on the potential use of a polygenic risk score (PRS) that combines thousands of genetic variants as a predictor fo...

ey0020.13-12 | Section | ESPEYB20

13.12. Embryo model completes gastrulation to neurulation and organogenesis

G Amadei , CE Handford , C Qiu , J De Jonghe , H Greenfeld , M Tran , BK Martin , DY Chen , A Aguilera-Castrejon , JH Hanna , MB Elowitz , F Hollfelder , J Shendure , DM Glover , M Zernicka-Goetz

In Brief: The authors created mouse embryos in the laboratory from a combination of multiple stem cell lines. These embryos were developed ex vivo up to the equivalent of day 8.5 post-fertilization. Embryos developed within an extraembryonic yolk sac and were similar to whole natural embryos, with defined forebrain and midbrain regions, a beating heart-like structure, a neural tube and somites, a tail bud containing neuromesodermal progenitors, a gut tube, and also pr...

ey0019.5-1 | Novel treatments for rare skeletal disorders | ESPEYB19

5.1. Targeting TGF-β for treatment of osteogenesis imperfecta

IW Song , SC Nagamani , D Nguyen , I Grafe , VR Sutton , FH Gannon , E Munivez , MM Jiang , A Tran , M Wallace , P Esposito , S Musaad , E Strudthoff , S McGuire , M Thornton , V Shenava , S Rosenfeld , S Huang , R Shypailo , E Orwoll , B Lee

J Clin Invest. 2022 Apr 1;132(7):e152571. doi: 10.1172/JCI152571.Abstract: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/35113812/In brief: Currently, there is no disease-specific therapy for osteogenesis imperfecta (OI) where most children, of all forms of OI, with significant fracture history, are managed by bisphosphonates...